{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:24:36Z","timestamp":1789885476501,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,4,18]],"date-time":"2016-04-18T00:00:00Z","timestamp":1460937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s40258-016-0243-4","type":"journal-article","created":{"date-parts":[[2016,4,18]],"date-time":"2016-04-18T09:10:49Z","timestamp":1460970649000},"page":"465-477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain"],"prefix":"10.1007","volume":"14","author":[{"given":"Eliazar","family":"Sabater","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Salar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Oyag\u00fcez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Collar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,18]]},"reference":[{"key":"243_CR1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-0609.1997.tb00982.x","volume":"59","author":"A Salar","year":"1997","unstructured":"Salar A, Fern\u00e1ndez de Sevilla A, Romagosa V, Domingo-Claros A, Gonzalez-Barca E, De Sanjos\u00e9 S, Pera J, Servitje O, Gra\u00f1ena A. Distribution and incidence rates of lymphoid neoplasms according to the REAL classification in a single institution. A prospective study of 940 cases. Eur J Haematol. 1997;59:231\u20137.","journal-title":"Eur J Haematol."},{"key":"243_CR2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin\u2019s lymphomas: distribution of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s Lymphoma Classification Project. Ann Oncol. 1998;9:717\u201320.","journal-title":"Ann Oncol."},{"issue":"6","key":"243_CR3","doi-asserted-by":"crossref","first-page":"916","DOI":"10.6004\/jnccn.2014.0086","volume":"12","author":"AD Zelenetz","year":"2014","unstructured":"Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin\u2019s Lymphomas, Version 2.2014. J Natl Compr Canc Netw. 2014;12(6):916\u201346.","journal-title":"J Natl Compr Canc Netw."},{"issue":"6","key":"243_CR4","doi-asserted-by":"crossref","first-page":"vi59","DOI":"10.1093\/annonc\/mdr388","volume":"22","author":"M Dreyling","year":"2011","unstructured":"Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(6):vi59\u201363.","journal-title":"Ann Oncol."},{"key":"243_CR5","doi-asserted-by":"crossref","unstructured":"Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E,. Dreyling M, Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) Ann Oncol. 2013;24:561\u201376.","DOI":"10.1093\/annonc\/mds517"},{"issue":"Suppl 3","key":"243_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428194.2011.629897","volume":"52","author":"A L\u00f3pez-Guillermo","year":"2011","unstructured":"L\u00f3pez-Guillermo A, Caballero D, Canales M, Provencio M, Rueda A, Salar A. Spanish Hematology and Hemotherapy Association; Oncological Group for the Treatment of Lymphatic Diseases; Spanish Lymphomas\/Autologous Bone Marrow Transplant Group. Clinical practice guidelines for first-line\/after-relapse treatment of patients with follicular lymphoma. Leuk Lymphoma. 2011;52(Suppl 3):1\u201314.","journal-title":"Leuk Lymphoma."},{"key":"243_CR7","unstructured":"Caballero D, Canales M, Provencio M, Rueda A, Salar A, L\u00f3pez-Guillermo A. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el tratamiento del Linfoma Folicular. Available at URL: http:\/\/www.guiasalud.es\/GPC\/GPC_474_Linfoma_folicular.pdf . Accessed on 2 June 2014."},{"issue":"10","key":"243_CR8","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00277-014-2103-3","volume":"93","author":"M Witzens-Harig","year":"2014","unstructured":"Witzens-Harig M, Fo\u00e1 R, Di Rocco A, van Hazel G, Chamone DF, Rowe JM, Arcaini L, Poddubnaya I, Ho AD, Ivanova V, Vranovsky A, Thurley D, Oertel S. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol. 2014;93(10):1717\u201324. doi: 10.1007\/s00277-014-2103-3 .","journal-title":"Ann Hematol."},{"issue":"12","key":"243_CR9","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/cncr.28659","volume":"120","author":"LJ Nastoupil","year":"2014","unstructured":"Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer. 2014;120(12):1830\u20137. doi: 10.1002\/cncr.28659 .","journal-title":"Cancer."},{"issue":"12","key":"243_CR10","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell\u2019olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506\u201313.","journal-title":"J Clin Oncol."},{"key":"243_CR11","unstructured":"European Medicines Agency. Summary of product characteristics Levact\u00ae. Available at URL: http:\/\/www.aemps.gob.es\/cima\/pdfs\/es\/ft\/72571\/FT_72571.pdf ."},{"issue":"9873","key":"243_CR12","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, D\u00fcrk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310.","journal-title":"Lancet."},{"key":"243_CR13","unstructured":"L\u00f3pez-Gonz\u00e1lez A, Quero C, Cruz MA, Sabin P, Aguiar D, G\u00f3mez Codina J, Llanos M, Rodr\u00edguez D, Lavernia J, Provencio M. Survival analysis of follicular lymphoma in a national registry with over a thousand patients: Impact by treatment groups. (abstract 3605). European Cancer Congress 2013. Amsterdam, Netherlands 2013, september 27th-October 1st. Available at URL: http:\/\/www.poster-submission.com\/search\/sresult . Accessed 29th May 2014."},{"issue":"3","key":"243_CR14","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","volume":"1","author":"A Salar","year":"2014","unstructured":"Salar A, Domingo-Dom\u00e9nech E, Panizo C, Nicol\u00e1s C, Bargay J, Munta\u00f1ola A, Canales M, Bello JL, Sancho JM, Tom\u00e1s JF, Rodr\u00edguez MJ, Pe\u00f1alver FJ, Grande C, S\u00e1nchez-Blanco JJ, Palomera L, Arranz R, Conde E, Garc\u00eda M, Garc\u00eda JF, Caballero D, Montalb\u00e1n C, For the Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula \u00d3sea (GELTAMO). First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematology. 2014;1(3):e104\u201311.","journal-title":"Lancet Haematology"},{"issue":"9759","key":"243_CR15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Ferm\u00e9 C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42\u201351.","journal-title":"Lancet."},{"key":"243_CR16","doi-asserted-by":"crossref","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853\u20138.","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"243_CR17","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing 2014; Vienna. URL http:\/\/www.R-project.org\/ ."},{"key":"243_CR18","unstructured":"Therneau T. A Package for Survival Analysis in S. R package version 2. 2014; 37\u20137. http:\/\/CRAN.R-project.org\/package=survival ."},{"key":"243_CR19","unstructured":"National Statistics Institute. Instituto Nacional de Estad\u00edstica (INE). Tablas de mortalidad de la poblaci\u00f3n de Espa\u00f1a 1991-2012. Available at URL: http:\/\/www.ine.es\/jaxi\/tabla.do?path=\/t20\/p319a\/serie\/p01\/l0\/&file=01001.px&type=pcaxis&L=0 . Accessed on 1 August 2014."},{"issue":"22","key":"243_CR20","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","volume":"23","author":"WT Swenson","year":"2005","unstructured":"Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23(22):5019\u201326.","journal-title":"J Clin Oncol."},{"key":"243_CR21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/annonc\/mdm543","volume":"19","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Donatti C, Hoskin P, Poynton C, Kettle PJ, Hancock B, Johnson S, Dyer MJ, Rule S, Walker M, Wild D. The impact of follicular lymphoma on health related quality of life. Ann Oncol. 2008;19:570\u20136.","journal-title":"Ann Oncol."},{"issue":"2","key":"243_CR22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3111\/13696998.2013.873044","volume":"17","author":"S Dewilde","year":"2014","unstructured":"Dewilde S, Woods B, Castaigne JG, Parker C, Dunlop W. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin\u2019s lymphoma in England and Wales. J Med Econ. 2014;17(2):111\u201324.","journal-title":"J Med Econ."},{"issue":"5","key":"243_CR23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10198-010-0244-4","volume":"11","author":"J L\u00f3pez-Bastida","year":"2010","unstructured":"L\u00f3pez-Bastida J, Oliva J, Anto\u00f1anzas F, Garc\u00eda-Alt\u00e9s A, Gisbert R, Mar J, Puig-Junoy J. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11(5):513\u201320.","journal-title":"Eur J Health Econ."},{"key":"243_CR24","unstructured":"General Council of Official Pharmaceutical Collegues Bot Plus 2.0. Available at URL: http:\/\/www.portalfarma.com . Accessed on 13 December 2013."},{"key":"243_CR25","unstructured":"Royal Decree-Law 8-2010. Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. Available at URL: http:\/\/www.boe.es\/boe\/dias\/2010\/05\/24\/pdfs\/BOE-A-2010-8228.pdf . Accessed on 13 December 2013."},{"key":"243_CR26","unstructured":"Ministry of Health. Ministerio de Sanidad, Servicios Sociales e Igualdad. Listado de medicamentos afectados por el RD-L 8\/2010. Available at URL. http:\/\/www.msssi.gob.es\/profesionales\/farmacia\/pdf\/deduccionesMay2014.pdf . Accessed on 13 December 2013."},{"key":"243_CR27","unstructured":"Oblikue Consulting. eSalud database. Available at URL: http:\/\/www.oblikue.com . Accessed on 13 December 2013."},{"key":"243_CR28","doi-asserted-by":"crossref","unstructured":"Sacrist\u00e1n JA, Oliva J, Del Llano J, Prieto L, Pinto JL. \u00bfQu\u00e9 es una tecnolog\u00eda sanitaria eficiente en Espa\u00f1a? [What is an efficient health technology in Spain?] Gac Sanit. 2002;16(4):334\u201343.","DOI":"10.1016\/S0213-9111(02)71933-X"},{"key":"243_CR29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ajh.21655","volume":"85","author":"RL Olin","year":"2010","unstructured":"Olin RL, Kanetsky PA, Ten Have TR, Nasta SD, Schuster SJ, Andreadis C. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. Am. J. Hematol. 2010;85:255\u201360.","journal-title":"Am. J. Hematol."},{"key":"243_CR30","doi-asserted-by":"crossref","unstructured":"Soini EJ, Martikainen JA, Vihervaara V, Mustonen K, Nousiainen T. Economic evaluation of sequential treatments for follicular non-Hodgkin lymphoma. Clin Ther. 2012;34(4):915\u2013925.e2.","DOI":"10.1016\/j.clinthera.2012.02.019"},{"issue":"15","key":"243_CR31","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1200\/jco.2012.30.15_suppl.6553","volume":"30","author":"W Su","year":"2012","unstructured":"Su W, Quon P, Whalen J, Ranganathan G, Wronski S, Mwamburi M, Knopf KB, Sterchele JA, Salvador CG, Stillman IO, Kadambi A. Cost-effectiveness analysis of bendamustine plus rituximab versus CHOP-R in treatment-naive patients with mantle cell (MCL) and indolent lymphomas (IL). J Clin Oncol. 2012;30(15):6553.","journal-title":"J Clin Oncol."},{"key":"243_CR32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1590\/S1135-57272012000200005","volume":"86","author":"AJ Castro G\u00f3mez","year":"2012","unstructured":"Castro G\u00f3mez AJ, L\u00f3pez-Guillermo A, Rueda Dom\u00ednguez A, Salar A, Varela Moreno C, Rubio-Terr\u00e9s C. An\u00e1lisis Coste-Efectividad del tratamiento de mantenimiento con rituximab en pacientes con linfoma folicular que responden a la terapia de inducci\u00f3n en primera l\u00ednea. Rev Esp Salud P\u00fablica. 2012;86:163\u201376.","journal-title":"Rev Esp Salud P\u00fablica."},{"issue":"3","key":"243_CR33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s10198-003-0182-5","volume":"4","author":"W Greiner","year":"2003","unstructured":"Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, Buxton M, Dolan P, Kind P, Krabbe P, Ohinmaa A, Parkin D, Roset M, Sintonen H, Tsuchiya A, de Charro F. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4(3):222\u201331.","journal-title":"Eur J Health Econ."},{"issue":"5","key":"243_CR34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40273-013-0043-8","volume":"31","author":"J Greenhalgh","year":"2013","unstructured":"Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Beale S, Dundar Y, Hockenhull J, Proudlove C, Chu P. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin\u2019s lymphoma : a NICE single technology appraisal. Pharmacoeconomics. 2013;31(5):403\u201313.","journal-title":"Pharmacoeconomics."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-016-0243-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-016-0243-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-016-0243-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T20:15:16Z","timestamp":1600460116000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-016-0243-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,18]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["243"],"URL":"https:\/\/doi.org\/10.1007\/s40258-016-0243-4","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,18]]}}}